FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biochemistry, particularly to using an anti-CGRP antagonist antibody for producing a therapeutic agent for preventing and/or treating chronic pain and/or chronic pain symptoms, and wherein the therapeutic agent is produced for peripheral administration.
EFFECT: using the above therapeutic agent for peripheral administration is effective for preventing and/or treating chronic pain.
3 cl, 9 dwg, 2 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATING VISCERAL PAIN BY ADMINISTERING ANTAGONIST ANTIBODIES AGAINST CALCITONIN GENE-RELATED PEPTIDE | 2010 |
|
RU2535074C2 |
| METHOD OF TREATING INFLAMMATORY PAIN | 2009 |
|
RU2467765C2 |
| TREATMENT OF INTERSTITIAL CYSTITIS | 2008 |
|
RU2570559C2 |
| PROTEINS BINDING PROSTAGLANDIN E2 AND USING THEM | 2009 |
|
RU2559525C2 |
| ANTI-AXL ANTIBODIES | 2008 |
|
RU2506276C2 |
| STABLE AQUEOUS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) ANTIBODY COMPOSITION | 2016 |
|
RU2699544C2 |
| ANTIBODIES TO PD-1 AND METHODS OF THEIR APPLICATION | 2015 |
|
RU2701797C2 |
| METHODS OF OSTEOARTHRITIS PAIN MANAGEMENT BY ADMINISTRATION OF NERVE GROWTH FACTOR ANTAGONIST AND COMPOSITIONS CONTAINING IT | 2006 |
|
RU2429013C2 |
| SELECTION OF PATIENTS WITH HEADACHE SUSCEPTIBLE TO ANTIBODIES AGAINST CALCITONIN GENE-RELATED PEPTIDE | 2018 |
|
RU2770066C2 |
| ANTI-PD-1 ANTIBODY AND USE THEREOF | 2017 |
|
RU2739610C1 |
